The goal is to confirm that weight loss is improving health, not only changing the scale
Going back to the STEP-UP trial with semaglutide it was seen in about 20% of patients in that trial as well on the 7.2mg dose
Although past meta-analyses reported substantial reductions in MACE with DPP-4 inhibitors [23], their conclusions were based on studies with small sample sizes and limited numbers of cardiovascular events, which have not been confirmed by the four CVOTs specifically designed to assess the CV safety of DPP-4 inhibitors
This is a clear and unequivocal example of forward-looking clinical research that allows us to expand the therapeutic opportunities for the treatment of obesity starting from a knowledge of the physiopathology and the experience gained with drugs that have made history (dulaglutide, tirzepatide, orforglipron, reatatutride etc.) How do they compare in weight-loss specifically for diabetics
[2] However, adding regular exercise and nutritional support may help sustain results post-treatment
Helpful Chart but Slow Start I followed the retatrutide dosage schedule chart closely, starting at 1 mg for two weeks then moving to 2 mg
.webp)
